Publications by authors named "Wilson Guzman"

Claim this Profile
X
XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies.
Ekta Patel, Natalia V Malkova, David Crowe, Magali Pederzoli-Ribeil, Damiano Fantini, Wilson Guzman

Mol Cancer Ther· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer.
Kurt A Jenkins, Miso Park, Magali Pederzoli-Ribeil, Ugur Eskiocak, Parker Johnson, Wilson Guzman

J Immunother Cancer· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity.
Ugur Eskiocak, Wilson Guzman, Benjamin Wolf, Christine Cummings, Lauren Milling

JCI Insight· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.
Chunxiao Xu, Yanping Zhang, P Alexander Rolfe, Vivian M Hernández, Wilson Guzman

Clin Cancer Res· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The immunocytokine NHS-IL12 as a potential cancer therapeutic.
Jonathan Fallon, Robert Tighe, Giorgio Kradjian, Wilson Guzman, Anna Bernhardt

Oncotarget· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis